IEX · Earnings call · 2026Q3T · Full report
Revenue Guidance and Outlook
IDEX CORP /DE/ · 2026-10-28 · Importance 74 · Surprise 68 · In source text
IDEX raised its 2026 organic growth outlook to 6.5%–6.8%, from 5%–6%. The company narrowed its full-year adjusted EBITDA margin outlook to 27.1%–27.3%. Adjusted EPS guidance increased by $0.16 at the midpoint to $8.91–$8.96, from $8.70–$8.85, representing double-digit year-over-year growth at the midpoint. Management said Q4 margins are expected to decline sequentially because of fewer production days and planned maintenance shutdowns.
Key facts
- IDEX raised its 2026 organic growth outlook to 6.5% to 6.8% from 5% to 6%.
- Management said IDEX was ahead of schedule in setting up HST for a high-single-digit growth rate and expected that to continue as the gap closed.
- IDEX expects growth in life sciences to return in 2027 and for life sciences to become additive to growth after dragging on HST for several years.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | +5.7% | IDEX raised its 2026 organic growth outlook to 6.5% to 6.8% from 5% to 6%. |